Engineered bacteria for augmentedin situtumor vaccination

Abstract

Engineered bacteria can be leveraged for in situ tumor vaccinations with their tumor-targeting ability and adjuvanticity. Engineering strategies like chemical modification, nanotechnology, and genetic engineering improve their safety and efficacy.

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

“…Living organisms like bacteria exhibit innate capabilities in modulating tumor microenvironment for augmenting CAR-T infiltration [ 50 , 51 ]. In 2022, Guo et al leveraged attenuated bacterial strain ( Brucella melitensis 16 M ΔvjbR ) as an adjuvant therapy for enhancing CAR-T treatment [ 52 ].…”

Genetically engineered bacteria: a new frontier in targeted drug delivery

“…Public opinion about GMOs is often divided, with concerns about their safety, ethics, and potential environmental impact contributing to skepticism and resistance. [167][168][169][170] In light of this, fostering public trust and acceptance is critical for the successful implementation of GEB applications in healthcare. This can be achieved through transparent communication about the benefits and risks of GEB, as well as the measures taken to ensure their safety.…”

Metal‐Free Atom Transfer Radical Polymerization to Prepare Recylable Micro‐Adjuvants for Dendritic Cell Vaccine

“…[2d,4] Presently, diverse techniques are employed to activate DCs, with adjuvants playing a crucial role in the construction of therapeutic cancer vaccines. Various adjuvants, including genetically modified bacteria, [5] cytokines, [6] proteins, [7] nanoparticles [8] and polysaccharides [9] have been utilized to modulate the behavior of DCs and other immune cells. Despite ongoing efforts to develop novel adjuvants for cancer immunotherapy, efficiency and safety are still the main challenges encountered by current DC vaccine adjuvants.…”